To download our brochure for MRX006 please enter your email address.
Dual cavity for triple therapy dry powder inhaler (DPI). MRX006 is based on the open-inhale-close principle. It is suitable as an AB-rated substitutable device for triple combination therapies.
It is designed to accommodate a combination formulation of 2 or more APIs, one of which may be chemically incompatible with the others, as with fluticasone, umeclidinium and vilanterol.
MRX006 offers unequalled technology tailored to current regulations and high-performance expectations.
Interested parties are invited to contact Merxin Ltd as soon as possible to secure access to a technology that will drive the next wave of inhaled finished dosage forms.
MRX006 uses Merxin Ltd’s proprietary designs and does not knowingly infringe any IP.